NCT04309201|Completed
Insulin Resistance, Sarcopenia and Plasma BAIBA Levels
Relationship With Muscle Wasting and Insulin Resistance in a Group of Non-diabetic Hemodialysis Patients.
Loading search results
Relationship With Muscle Wasting and Insulin Resistance in a Group of Non-diabetic Hemodialysis Patients.
Sponsor study identifier
observational
150
1 country
1
Study Start
March 10, 2020
Actual (reported)Primary Completion
December 31, 2020
Actual (reported)Study Completion
December 31, 2020
Actual (reported)Insulin resistance (IR) is an early metabolic alteration in chronic kidney disease (CKD) patients, becoming almost universal in those who reach the end stage of kidney failure. The skeletal muscle represents the primary site of IR in CKD, and alterations at sites beyond the insulin receptor are recognized as the main defect underlying IR in this condition. The etiology of IR in CKD is multifactorial in nature and may be secondary to disturbances that are prominent in renal diseases, including physical inactivity, chronic inflammation, oxidative stress, vitamin D deficiency, metabolic acidosis, anemia, adipokine derangement, and altered gut microbiome. IR has been solidly associated with intermediate mechanisms leading to cardiovascular (CV) disease in CKD including left ventricular hypertrophy, vascular dysfunction, and atherosclerosis. Recent studies have identified a muscle factor β-aminoisobutyric acid (BAIBA), which is produced by skeletal muscle during physical activity. BAIBA have been found to link with sedentary life style, abdominal obesity, and impairments in carbohydrate and lipid metabolism. A few studies have shown that BAIBA can protect from diet-induced obesity in animal models. It induces transition of white adipose tissue to a "beige" phenotype, which induces fatty acids oxidation and increases insulin sensitivity. While the exact mechanisms of BAIBA-induced metabolic effects are still not well understood, the aim of this study is want to study its relationship with muscle wasting and insulin resistance in a group of non-diabetic hemodialysis patients.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 10, 2020
Actual (reported)March 12, 2020
Actual (reported)March 16, 2020
Actual (reported)December 31, 2020
Actual (reported)December 31, 2020
Actual (reported)Analysis of biomarkers of β-aminoisobutyric Acid( L-BAIBA) levels
BAIBA can protect from diet-induced obesity in animal models. It induces transition of white adipose tissue to a "beige" phenotype, which induces fatty acids oxidation and increases insulin sensitivity.
1 years
Presence of Sarcopenia
1 years
hemodialysis (HD) patients
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan
Plasma
Paik Seong Lim, PhD
Tungs' Taichung Metroharbour Hospital
150 participants (actual enrollment reported by the registry).
First Submitted
March 12, 2020
First Posted
March 16, 2020
Study Start
March 10, 2020
Actual (reported)Investigation of Impacts of Vibration on Muscular Strength and Functional Performance of Upper Limbs of Older Adults
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2020
Actual (reported)Study Completion
December 31, 2020
Actual (reported)Last Updated
February 1, 2021
Record last verified: 2021-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: